Icotrokinra Maintains Psoriasis Responses With Continuous Treatment

Continuous treatment with icotrokinra resulted in durable psoriasis control through one year, while treatment withdrawal was associated with rapid loss of response, according to “Maintenance of Response With Icotrokinra for the Treatment of Moderate-to-Severe Plaque Psoriasis: Results From the Phase 3 ICONIC-LEAD Trial,” a poster by Jennifer Soung, MD, et al presented as part of the “Best of the Best at Maui Derm” late breakers session at Maui Derm Hawaii 2026.

Among adult responders at Week 24, 89% maintained PASI 75 and 84% maintained PASI 90 with continued treatment through Week 52. Adolescents demonstrated similarly robust and durable responses.

No new safety signals were identified through one year of treatment, the authors reported.

“This is the first oral therapy I have seen that really starts to close the gap between orals and biologics,” said Jason E. Hawkes, MD. “Historically, choosing an oral meant compromising on efficacy. That may no longer be the case.”

Linda Stein Gold, MD, highlighted the adolescent findings.

“Giving a teenager one pill a day and seeing nearly 90% achieve PASI 90 at 1 year, with a clean safety profile, is incredibly compelling,” she said.